SCHEMBL2867370

SCHEMBL2867370

CC(C)(C)OC(=O)N1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.53
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
CHRM2 P08172 1/20 0.49
CHRM4 P08173 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
DTYMK P23919 1/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
TACR1 P25103 1/20 0.46
STS P08842 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27872075 0.85 GPR119 (0.44) GPR119CKS1BSKP1SKP2CHRM2
SCHEMBL27906266 0.82 TSHR (0.57) KDM4EPOLBKMT2AMAPTALDH1A1
SCHEMBL17523154 0.80 MGLL (0.56) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL7666266 0.79 KMT2A (0.51) CKS1BSKP1SKP2KMT2AALDH1A1
SCHEMBL955395 0.79 SMN1; SMN2 (0.40) CHRM4CHRM1CHRM3MEN1KMT2A
SCHEMBL1458887 0.78 GPR119 (0.76) GPR119CKS1BSKP1SKP2MEN1
SCHEMBL952359 0.78 GAA (0.60) GPR119CKS1BSKP1SKP2CHRM2
SCHEMBL1374093 0.78 MEN1 (0.68) GPR119KDM4EPKMPOLBMEN1
SCHEMBL3397463 0.78 GPR119 (0.50) GPR119CHRM3KDM4EPKMMEN1
SCHEMBL13464773 0.77 KDM4E (0.55) GPR119CKS1BSKP1SKP2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022246092-A1 MACROCYCLIC COMPOUNDS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2022-11-24 WO disclosed
CN-104693193-A Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2015-06-10 CN disclosed
CN-102822165-B Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2015-02-25 CN disclosed
CN-102822165-A Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2012-12-12 CN disclosed
CN-102480943-A Opsin binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS INC 2012-05-30 CN disclosed
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 GPR119 75/4885CKS1B 2809/4885SKP1 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.